Insider Selling: Vaxcyte (NASDAQ:PCVX) EVP Sells $127,507.50 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 2,250 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $56.67, for a total transaction of $127,507.50. Following the completion of the transaction, the executive vice president owned 145,435 shares in the company, valued at approximately $8,241,801.45. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The shares were sold at an average price of $59.52, for a total transaction of $79,399.68.
• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The stock was sold at an average price of $61.16, for a total transaction of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The stock was sold at an average price of $61.07, for a total transaction of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $53.86, for a total transaction of $121,185.00.

Vaxcyte Price Performance

Vaxcyte stock traded up $0.43 during trading hours on Friday, hitting $56.48. The company had a trading volume of 2,399,621 shares, compared to its average volume of 1,387,746. The firm has a 50-day moving average of $58.63 and a 200 day moving average of $56.18. The firm has a market cap of $8.40 billion, a PE ratio of -7.40 and a beta of 1.23. Vaxcyte, Inc. has a one year low of $39.87 and a one year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.09. During the same period in the prior year, the firm posted ($1.22) EPS. As a group, research analysts expect that Vaxcyte, Inc. will post -7.6 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on PCVX. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Bank of America lowered their price objective on Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a research note on Monday. Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $110.00 price target on shares of Vaxcyte in a research report on Friday, September 25th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Vaxcyte presently has an average rating of “Moderate Buy” and an average price target of $104.40.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. IFP Advisors Inc lifted its stake in shares of Vaxcyte by 72.8% in the 2nd quarter. IFP Advisors Inc now owns 560 shares of the company’s stock valued at $33,000 after acquiring an additional 236 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Vaxcyte by 33.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after acquiring an additional 184 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in Vaxcyte by 1,924.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 830 shares of the company’s stock worth $38,000 after acquiring an additional 789 shares during the last quarter. Capital Advisors Ltd. LLC bought a new position in Vaxcyte in the first quarter valued at about $58,000. Finally, Eurizon Capital SGR S.p.A. acquired a new stake in shares of Vaxcyte during the fourth quarter valued at about $63,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte’s lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.